New vaccine aims to shield transplant patients from Cancer-Causing virus
NCT ID NCT06741072
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 23 times
Summary
This early-stage trial tests a vaccine (OSU-2131) designed to help the immune system fight Epstein-Barr virus (EBV), which can cause cancer in people with weakened immune systems. The study includes healthy volunteers and patients waiting for a solid organ transplant, who are at higher risk due to anti-rejection drugs. The goal is to see if the vaccine is safe and triggers a strong immune response against EBV.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE, STAGE 5 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.